Sumitomo Mitsui Trust Group Inc. Sells 117,438 Shares of AbbVie Inc. $ABBV

Sumitomo Mitsui Trust Group Inc. lowered its position in AbbVie Inc. (NYSE:ABBV) by 3.0% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 3,828,108 shares of the company’s stock after selling 117,438 shares during the period. AbbVie comprises about 0.6% of Sumitomo Mitsui Trust Group Inc.’s portfolio, making the stock its 27th largest holding. Sumitomo Mitsui Trust Group Inc.’s holdings in AbbVie were worth $1,001,395,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. purchased a new position in AbbVie during the third quarter worth about $140,729,000. Stevens Capital Partners increased its stake in AbbVie by 39.4% in the 3rd quarter. Stevens Capital Partners now owns 1,427 shares of the company’s stock valued at $373,000 after buying an additional 403 shares during the last quarter. Profund Advisors LLC increased its stake in AbbVie by 8.6% in the 3rd quarter. Profund Advisors LLC now owns 28,417 shares of the company’s stock valued at $7,434,000 after buying an additional 2,249 shares during the last quarter. Vise Technologies Inc. increased its stake in AbbVie by 21.7% in the 3rd quarter. Vise Technologies Inc. now owns 143,948 shares of the company’s stock valued at $37,655,000 after buying an additional 25,704 shares during the last quarter. Finally, Investment Partners LTD. lifted its position in shares of AbbVie by 82.2% during the 3rd quarter. Investment Partners LTD. now owns 10,925 shares of the company’s stock worth $2,858,000 after buying an additional 4,928 shares in the last quarter. 70.23% of the stock is owned by institutional investors.

Insider Buying and Selling at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.06% of the company’s stock.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q3 results beat expectations. Adjusted earnings per share were $3.82 versus the $3.73 analyst consensus, while revenue rose 10.3% year over year to $17.404 billion, ahead of the $17.32 billion estimate. Adjusted EPS more than doubled from the prior-year quarter. AbbVie Reports Third-Quarter 2026 Financial Results
• Positive Sentiment: Immunology and neuroscience provided strong momentum. Skyrizi generated $5.776 billion in revenue and Rinvoq produced $2.706 billion, helping immunology revenue increase 16.3%. Neuroscience revenue climbed 19.4%, led by Vraylar, therapeutic Botox, Ubrelvy and Qulipta. AbbVie Lifts 2026 Outlook as Immunology, Neuroscience Quarterly Sales Beat Views
• Positive Sentiment: Management raised guidance and its dividend. AbbVie increased its 2026 adjusted EPS outlook to $13.95–$13.99 from $13.76–$13.96, despite including $0.69 per share of year-to-date acquired in-process research and development and milestone expenses. The company also announced a 5.2% dividend increase beginning with the February 2027 payment. AbbVie Raises FY26 Adjusted EPS Outlook and Boosts Dividend
• Positive Sentiment: Pipeline expansion supports longer-term confidence. AbbVie completed its acquisition of Apogee Therapeutics, strengthening its immunology pipeline, while Qulipta also outperformed topiramate in a Phase 3 migraine-prevention study. AbbVie QULIPTA Phase 3 Migraine Prevention Trial
• Negative Sentiment: Investors remain focused on valuation and concentration risks. Humira revenue fell 31.2% to $683 million, while aesthetics revenue declined 1.4%. After a substantial multiyear rally and trading near its 52-week high, analysts question whether additional valuation expansion is justified and how effectively AbbVie can sustain growth beyond Skyrizi and Rinvoq. Skyrizi and Rinvoq Dominate AbbVie Q3

AbbVie Trading Up 1.4%

ABBV opened at $294.80 on Friday. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $298.74. The company has a market cap of $520.85 billion, a PE ratio of 50.74, a price-to-earnings-growth ratio of 1.35 and a beta of 0.24. The company has a 50 day moving average of $269.35 and a 200 day moving average of $237.23.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.73 by $0.09. The business had revenue of $17.40 billion for the quarter, compared to analysts’ expectations of $17.32 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.86 EPS. Research analysts forecast that AbbVie Inc. will post 13.92 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a $1.73 dividend. The ex-dividend date is Thursday, October 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.3%. AbbVie’s payout ratio is 195.48%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Royal Bank Of Canada restated an “outperform” rating and issued a $280.00 target price on shares of AbbVie in a research note on Tuesday, October 13th. Leerink Partners increased their price target on AbbVie from $245.00 to $279.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. Morgan Stanley increased their price target on AbbVie from $296.00 to $310.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. Wolfe Research upgraded AbbVie from a “peer perform” rating to an “outperform” rating and lifted their price target for the stock from $235.00 to $300.00 in a report on Thursday, August 13th. Finally, Cantor Fitzgerald boosted their price objective on AbbVie from $285.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday, October 8th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and an average price target of $279.86.

About AbbVie

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.